ArticleDiscover oncology2025
Exploring targeted therapies against RFPL3 for non-small cell lung cancer with lymph node metastasis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, marked by its aggressive nature and high likelihood of metastasis. The precise function of ret finger protein-like 3 (RFPL3) in NSCLC progression remains incompletely understood.
methodsThis study measured RFPL3 expression in NSCLC by immunohistochemistry, qPCR, and Western blot. RFPL3's effects on proliferation were assessed with CCK-8 and colony formation assays. Transwell and wound-healing assays evaluated its role in invasion, metastasis, and EMT. In vitro and in vivo studies determined RFPL3's mechanisms driving EMT and lymphatic metastasis.
resultsRFPL3 was overexpressed in NSCLC tissues, correlating with lymphatic metastasis and poor prognosis, establishing it as a distinct prognostic risk factor. Knockdown reduced NSCLC cell proliferation, invasion, and metastasis, while overexpression enhanced these malignant phenotypes. RFPL3 increased EMT-related protein expression by western blot, promoting tumor cell metastasis. In vivo, RFPL3 overexpression accelerated tumor growth and lymphatic metastasis in mice.
conclusionThis study revealed the critical role of RFPL3 in NSCLC, suggesting that RFPL3 might serve as both a biomarker and a therapeutic target for this type of cancer, which provides new insight for improving patient prognoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.